{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:29:46Z","timestamp":1794536986333,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"1. Municipal Program of Science and Technology in Suzhou"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Discovering new molecular targets for non-small cell lung cancer (NSCLC) is critically important. Enhanced mitochondrial function can promote NSCLC progression by enabling metabolic reprogramming, resistance to apoptosis, and increased cell proliferation. Mitochondrial carrier homolog 2 (MTCH2), located in the outer mitochondrial membrane, is pivotal in regulating mitochondrial activities. This study examines MTCH2 expression and its functional role in NSCLC. Bioinformatic analysis showed that MTCH2 is overexpressed in NSCLC tissues, correlating with poor prognosis and other key clinical parameters of the patients. In addition, single-cell sequencing data revealed higher MTCH2 expression levels in cancer cells of NSCLC tumor mass. Moreover, MTCH2 is also upregulated in locally-treated NSCLC tissues and multiple primary\/established human NSCLC cells. In various NSCLC cells, silencing MTCH2 via targeted shRNA or knockout (KO) using the CRISPR\/Cas9 method significantly hindered cell proliferation, migration and invasion, while inducing apoptosis. MTCH2 knockdown or KO robustly impaired mitochondrial function, as indicated by reduced mitochondrial respiration, decreased complex I activity, lower ATP levels, lower mitochondrial membrane potential (mitochondrial depolarization), and increased reactive oxygen species (ROS) production. Conversely, ectopic overexpression of MTCH2 in primary NSCLC cells enhanced mitochondrial complex I activity and ATP production, promoting cell proliferation and migration. In vivo, the intratumoral injection of MTCH2 shRNA adeno-associated virus (aav) impeded the growth of subcutaneous xenografts of primary NSCLC cells in nude mice. In MTCH2 shRNA aav-injected NSCLC xenograft tissues, there was decreases in MTCH2 expression, mitochondrial complex I activity, ATP content, and the glutathione (GSH)\/glutathione disulfide (GSSG) ratio, but increase in thiobarbituric acid reactive substances (TBAR) activity. Additionally, MTCH2 silencing led to reduced Ki-67 staining but increased apoptosis in NSCLC xenografts. Collectively, these findings demonstrate that overexpressed MTCH2 promotes NSCLC cell growth potentially through the maintenance of mitochondrial hyper-function, highlighting MTCH2 as a novel and promising therapeutic target for treating this disease.<\/jats:p>","DOI":"10.1038\/s41419-025-07419-0","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:12:53Z","timestamp":1739459573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mitochondrial carrier homolog 2 is important for mitochondrial functionality and non-small cell lung cancer cell growth"],"prefix":"10.1038","volume":"16","author":[{"given":"Yong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peidong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7326-7450","authenticated-orcid":false,"given":"Chang-gong","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1281-7133","authenticated-orcid":false,"given":"Yong-hua","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"7419_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"7419_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"7419_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535\u201354.","journal-title":"Lancet"},{"key":"7419_CR4","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"M Arbyn","year":"2020","unstructured":"Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191\u2013e203.","journal-title":"Lancet Glob Health"},{"key":"7419_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299\u2013311.","journal-title":"Lancet"},{"key":"7419_CR6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(16)31340-X","volume":"388","author":"CT Hiley","year":"2016","unstructured":"Hiley CT, Le Quesne J, Santis G, Sharpe R, de Castro DG, Middleton G, et al. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet. 2016;388:1002\u201311.","journal-title":"Lancet"},{"key":"7419_CR7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour KC, Riely GJ. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. JAMA. 2019;322:764\u201374.","journal-title":"JAMA"},{"key":"7419_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1051\/bmdcn\/2017070423","volume":"7","author":"CY Huang","year":"2017","unstructured":"Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK. A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomedicine. 2017;7:23.","journal-title":"Biomedicine"},{"key":"7419_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/0284186X.2017.1404634","volume":"57","author":"HH Vestergaard","year":"2018","unstructured":"Vestergaard HH, Christensen MR, Lassen UN. A systematic review of targeted agents for non-small cell lung cancer. Acta Oncol. 2018;57:176\u201386.","journal-title":"Acta Oncol"},{"key":"7419_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446\u201354.","journal-title":"Nature"},{"key":"7419_CR11","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","volume":"1","author":"C Gridelli","year":"2015","unstructured":"Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009.","journal-title":"Nat Rev Dis Primers"},{"key":"7419_CR12","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.7150\/thno.43142","volume":"10","author":"P Xu","year":"2020","unstructured":"Xu P, Jiang L, Yang Y, Wu M, Liu B, Shi Y, et al. PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting Nrf2 protein degradation. Theranostics. 2020;10:3767\u201378.","journal-title":"Theranostics"},{"key":"7419_CR13","doi-asserted-by":"publisher","first-page":"7474","DOI":"10.7150\/thno.35582","volume":"9","author":"F Li","year":"2019","unstructured":"Li F, Li X, Li Z, Ji W, Lu S, Xia W. betaKlotho is identified as a target for theranostics in non-small cell lung cancer. Theranostics. 2019;9:7474\u201389.","journal-title":"Theranostics"},{"key":"7419_CR14","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","volume":"157","author":"EN Imyanitov","year":"2021","unstructured":"Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. Crit Rev Oncol Hematol. 2021;157:103194.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7419_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bcp.2014.05.011","volume":"90","author":"C Fumarola","year":"2014","unstructured":"Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Targeting PI3K\/AKT\/mTOR pathway in non small cell lung cancer. Biochem Pharmacol. 2014;90:197\u2013207.","journal-title":"Biochem Pharmacol"},{"key":"7419_CR16","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-13-2088","volume":"20","author":"PM Forde","year":"2014","unstructured":"Forde PM, Brahmer JR, Kelly RJ. New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer. Clin Cancer Res. 2014;20:2244\u20138.","journal-title":"Clin Cancer Res"},{"key":"7419_CR17","first-page":"167","volume":"27","author":"S Jonna","year":"2019","unstructured":"Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discov Med. 2019;27:167\u201370.","journal-title":"Discov Med"},{"key":"7419_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ctrv.2013.08.006","volume":"40","author":"S Heavey","year":"2014","unstructured":"Heavey S, O\u2019Byrne KJ, Gately K. Strategies for co-targeting the PI3K\/AKT\/mTOR pathway in NSCLC. Cancer Treat Rev. 2014;40:445\u201356.","journal-title":"Cancer Treat Rev"},{"key":"7419_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/cr.2017.155","volume":"28","author":"PE Porporato","year":"2018","unstructured":"Porporato PE, Filigheddu N, Bravo-San Pedro JM, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Research. 2018;28:265\u201380.","journal-title":"Cell Research"},{"key":"7419_CR20","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.trecan.2017.10.006","volume":"3","author":"PJ Burke","year":"2017","unstructured":"Burke PJ. Mitochondria, Bioenergetics and Apoptosis in Cancer. Trends Cancer. 2017;3:857\u201370.","journal-title":"Trends Cancer"},{"key":"7419_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cell.2016.07.002","volume":"166","author":"S Vyas","year":"2016","unstructured":"Vyas S, Zaganjor E, Haigis MC. Mitochondria and Cancer. Cell. 2016;166:555\u201366.","journal-title":"Cell"},{"key":"7419_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1712","volume":"11","author":"SE Weinberg","year":"2015","unstructured":"Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol. 2015;11:9\u201315.","journal-title":"Nat Chem Biol"},{"key":"7419_CR23","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1158\/0008-5472.CAN-15-0491","volume":"75","author":"A Viale","year":"2015","unstructured":"Viale A, Corti D, Draetta GF. Tumors and mitochondrial respiration: a neglected connection. Cancer Res. 2015;75:3685\u20136.","journal-title":"Cancer Res"},{"key":"7419_CR24","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.7150\/ijbs.82217","volume":"19","author":"Y Xia","year":"2023","unstructured":"Xia Y, He C, Hu Z, Wu Z, Hui Y, Liu YY, et al. The mitochondrial protein YME1 Like 1 is important for non-small cell lung cancer cell growth. Int J Biol Sci. 2023;19:1778\u201390.","journal-title":"Int J Biol Sci"},{"key":"7419_CR25","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.7150\/ijbs.78354","volume":"18","author":"JZ Zhang","year":"2022","unstructured":"Zhang JZ, Liu J, Xu YX, Pu WY, Shen MJ, Jiang KQ, et al. Identification of the mitochondrial protein ADCK2 as a therapeutic oncotarget of NSCLC. Int J Biol Sci. 2022;18:6163\u201375.","journal-title":"Int J Biol Sci"},{"key":"7419_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04039-2","volume":"12","author":"T Zhou","year":"2021","unstructured":"Zhou T, Sang YH, Cai S, Xu C, Shi MH. The requirement of mitochondrial RNA polymerase for non-small cell lung cancer cell growth. Cell Death Dis. 2021;12:751.","journal-title":"Cell Death Dis"},{"key":"7419_CR27","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1158\/1541-7786.MCR-13-0481","volume":"12","author":"J Agorreta","year":"2014","unstructured":"Agorreta J, Hu J, Liu D, Delia D, Turley H, Ferguson DJ, et al. TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC. Mol Cancer Res. 2014;12:660\u20139.","journal-title":"Mol Cancer Res"},{"key":"7419_CR28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1517\/13543784.2014.899350","volume":"23","author":"FE Lennon","year":"2014","unstructured":"Lennon FE, Salgia R. Mitochondrial dynamics: biology and therapy in lung cancer. Expert Opin Investig Drugs. 2014;23:675\u201392.","journal-title":"Expert Opin Investig Drugs"},{"key":"7419_CR29","doi-asserted-by":"publisher","first-page":"e201303019","DOI":"10.5936\/csbj.201303019","volume":"6","author":"ER Roberts","year":"2013","unstructured":"Roberts ER, Thomas KJ. The role of mitochondria in the development and progression of lung cancer. Comput Struct Biotechnol J. 2013;6:e201303019.","journal-title":"Comput Struct Biotechnol J"},{"key":"7419_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1126\/science.add1856","volume":"378","author":"A Guna","year":"2022","unstructured":"Guna A, Stevens TA, Inglis AJ, Replogle JM, Esantsi TK, Muthukumar G, et al. MTCH2 is a mitochondrial outer membrane protein insertase. Science. 2022;378:317\u201322.","journal-title":"Science"},{"key":"7419_CR31","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.2147\/DDDT.S460448","volume":"18","author":"X Peng","year":"2024","unstructured":"Peng X, Yang Y, Hou R, Zhang L, Shen C, Yang X, et al. MTCH2 in Metabolic Diseases, Neurodegenerative Diseases, Cancers, Embryonic Development and Reproduction. Drug Des Devel Ther. 2024;18:2203\u201313.","journal-title":"Drug Des Devel Ther"},{"key":"7419_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/ncb2057","volume":"12","author":"Y Zaltsman","year":"2010","unstructured":"Zaltsman Y, Shachnai L, Yivgi-Ohana N, Schwarz M, Maryanovich M, Houtkooper RH, et al. MTCH2\/MIMP is a major facilitator of tBID recruitment to mitochondria. Nat Cell Biol. 2010;12:553\u201362.","journal-title":"Nat Cell Biol"},{"key":"7419_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s10020-020-00261-4","volume":"27","author":"Q Yuan","year":"2021","unstructured":"Yuan Q, Yang W, Zhang S, Li T, Zuo M, Zhou X, et al. Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma. Mol Med. 2021;27:7.","journal-title":"Mol Med"},{"key":"7419_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28172","volume":"10","author":"W Jiang","year":"2024","unstructured":"Jiang W, Miao Y, Xing X, Liu S, Xing W, Qian F. MTCH2 stimulates cellular proliferation and cycles via PI3K\/Akt pathway in breast cancer. Heliyon. 2024;10:e28172.","journal-title":"Heliyon"},{"key":"7419_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3892\/etm.2023.11862","volume":"25","author":"R Li","year":"2023","unstructured":"Li R, He H, He X. APOC1 promotes the progression of osteosarcoma by binding to MTCH2. Exp Ther Med. 2023;25:163.","journal-title":"Exp Ther Med"},{"key":"7419_CR36","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.7150\/ijbs.72526","volume":"18","author":"TF Chen","year":"2022","unstructured":"Chen TF, Hao HF, Zhang Y, Chen XY, Zhao HS, Yang R, et al. HBO1 induces histone acetylation and is important for non-small cell lung cancer cell growth. Int J Biol Sci. 2022;18:3313\u201323.","journal-title":"Int J Biol Sci"},{"key":"7419_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03655-2","volume":"12","author":"YC Xia","year":"2021","unstructured":"Xia YC, Zha JH, Sang YH, Yin H, Xu GQ, Zhen J, et al. AMPK activation by ASP4132 inhibits non-small cell lung cancer cell growth. Cell Death Dis. 2021;12:365.","journal-title":"Cell Death Dis"},{"key":"7419_CR38","doi-asserted-by":"publisher","first-page":"9911784","DOI":"10.1155\/2021\/9911784","volume":"2021","author":"G Chen","year":"2021","unstructured":"Chen G, Mo S, Yuan D. Upregulation Mitochondrial Carrier 1 (MTCH1) Is Associated with Cell Proliferation, Invasion, and Migration of Liver Hepatocellular Carcinoma. Biomed Res Int. 2021;2021:9911784.","journal-title":"Biomed Res Int"},{"key":"7419_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06811-6","volume":"15","author":"F Cheng","year":"2024","unstructured":"Cheng F, Huang H, Yin S, Liu JS, Sun P. Expression and functional implications of YME1L in nasopharyngeal carcinoma. Cell Death Dis. 2024;15:423.","journal-title":"Cell Death Dis"},{"key":"7419_CR40","doi-asserted-by":"publisher","first-page":"102311","DOI":"10.1016\/j.redox.2022.102311","volume":"52","author":"M Ding","year":"2022","unstructured":"Ding M, Shi R, Cheng S, Li M, De D, Liu C, et al. Mfn2-mediated mitochondrial fusion alleviates doxorubicin-induced cardiotoxicity with enhancing its anticancer activity through metabolic switch. Redox Biol. 2022;52:102311.","journal-title":"Redox Biol"},{"key":"7419_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-023-02074-6","volume":"10","author":"KH Prazanowska","year":"2023","unstructured":"Prazanowska KH, Lim SB. An integrated single-cell transcriptomic dataset for non-small cell lung cancer. Sci Data. 2023;10:167.","journal-title":"Sci Data"},{"key":"7419_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16164-1","volume":"11","author":"N Kim","year":"2020","unstructured":"Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020;11:2285.","journal-title":"Nat Commun"},{"key":"7419_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14651-y","volume":"7","author":"TW Huang","year":"2017","unstructured":"Huang TW, Lin KF, Lee CH, Chang H, Lee SC, Shieh YS. The role of Thyroid Transcription Factor-1 and Tumor differentiation in Resected Lung Adenocarcinoma. Sci Rep. 2017;7:14222.","journal-title":"Sci Rep"},{"key":"7419_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5858\/arpa.2011-0320-OA","volume":"136","author":"BM Turner","year":"2012","unstructured":"Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012;136:163\u201371.","journal-title":"Arch Pathol Lab Med"},{"key":"7419_CR45","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/cncy.20108","volume":"118","author":"LM Stoll","year":"2010","unstructured":"Stoll LM, Johnson MW, Gabrielson E, Askin F, Clark DP, Li QK. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol. 2010;118:441\u20139.","journal-title":"Cancer Cytopathol"},{"key":"7419_CR46","doi-asserted-by":"crossref","unstructured":"Schrank Z, Chhabra G, Lin L, Iderzorig T, Osude C, Khan N, et al. Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance. Cancers. 2018;10:224.","DOI":"10.3390\/cancers10070224"},{"key":"7419_CR47","doi-asserted-by":"crossref","unstructured":"Tang S, Qin C, Hu H, Liu T, He Y, Guo H, et al. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells. 2022;11:320.","DOI":"10.3390\/cells11030320"},{"key":"7419_CR48","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41423-020-00577-5","volume":"18","author":"F Zhou","year":"2021","unstructured":"Zhou F, Qiao M, Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol Immunol. 2021;18:279\u201393.","journal-title":"Cell Mol Immunol"},{"key":"7419_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07519-w","volume":"9","author":"A Bahat","year":"2018","unstructured":"Bahat A, Goldman A, Zaltsman Y, Khan DH, Halperin C, Amzallag E, et al. MTCH2-mediated mitochondrial fusion drives exit from naive pluripotency in embryonic stem cells. Nat Commun. 2018;9:5132.","journal-title":"Nat Commun"},{"key":"7419_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8901","volume":"6","author":"M Maryanovich","year":"2015","unstructured":"Maryanovich M, Zaltsman Y, Ruggiero A, Goldman A, Shachnai L, Zaidman SL, et al. An MTCH2 pathway repressing mitochondria metabolism regulates haematopoietic stem cell fate. Nat Commun. 2015;6:7901.","journal-title":"Nat Commun"},{"key":"7419_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/srep44401","volume":"7","author":"A Ruggiero","year":"2017","unstructured":"Ruggiero A, Aloni E, Korkotian E, Zaltsman Y, Oni-Biton E, Kuperman Y, et al. Loss of forebrain MTCH2 decreases mitochondria motility and calcium handling and impairs hippocampal-dependent cognitive functions. Sci Rep. 2017;7:44401.","journal-title":"Sci Rep"},{"key":"7419_CR52","doi-asserted-by":"crossref","unstructured":"Guo L. Mitochondrial permeability transition mediated by MTCH2 and F-ATP synthase contributes to ferroptosis defense. FEBS Lett. 2024.","DOI":"10.1002\/1873-3468.15008"},{"key":"7419_CR53","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3892\/ol.2024.14625","volume":"28","author":"G Sun","year":"2024","unstructured":"Sun G, Song Y, Li C, Sun B, Li C, Sun J, et al. MTCH2 promotes the malignant progression of ovarian cancer through the upregulation of AIMP2 expression levels, mitochondrial dysfunction and by mediating energy metabolism. Oncol Lett. 2024;28:492.","journal-title":"Oncol Lett"},{"key":"7419_CR54","doi-asserted-by":"publisher","first-page":"102654","DOI":"10.1016\/j.jbc.2022.102654","volume":"298","author":"R Hall","year":"2022","unstructured":"Hall R, Yuan S, Wood K, Katona M, Straub AC. Cytochrome b5 reductases: Redox regulators of cell homeostasis. J Biol Chem. 2022;298:102654.","journal-title":"J Biol Chem"},{"key":"7419_CR55","doi-asserted-by":"publisher","first-page":"16378","DOI":"10.1021\/bi961895o","volume":"35","author":"MJ Rodriguez-Maranon","year":"1996","unstructured":"Rodriguez-Maranon MJ, Qiu F, Stark RE, White SP, Zhang X, Foundling SI, et al. 13C NMR spectroscopic and X-ray crystallographic study of the role played by mitochondrial cytochrome b5 heme propionates in the electrostatic binding to cytochrome c. Biochemistry. 1996;35:16378\u201390.","journal-title":"Biochemistry"},{"key":"7419_CR56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1107\/S0907444995007827","volume":"52","author":"RC Durley","year":"1996","unstructured":"Durley RC, Mathews FS. Refinement and structural analysis of bovine cytochrome b5 at 1.5 A resolution. Acta Crystallogr D Biol Crystallogr. 1996;52:65\u201376.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"7419_CR57","doi-asserted-by":"crossref","unstructured":"Bai X, Zhang Z, Li X, Yang Y, Ding S. FUNDC1: An Emerging Mitochondrial and MAMs Protein for Mitochondrial Quality Control in Heart Diseases. Int J Mol Sci. 2023;24:9151.","DOI":"10.3390\/ijms24119151"},{"key":"7419_CR58","doi-asserted-by":"publisher","first-page":"114891","DOI":"10.1016\/j.bcp.2021.114891","volume":"197","author":"H Liu","year":"2022","unstructured":"Liu H, Zang C, Yuan F, Ju C, Shang M, Ning J, et al. The role of FUNDC1 in mitophagy, mitochondrial dynamics and human diseases. Biochem Pharmacol. 2022;197:114891.","journal-title":"Biochem Pharmacol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07419-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07419-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07419-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:15:10Z","timestamp":1739459710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07419-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7419"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07419-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Human tissues and primary human cells were provided by the participants with written-informed consent. The management of these human tissue samples and cells followed protocols sanctioned by the Soochow University Ethics Committee (SDY-2022-158-1#), aligning with the Declaration of Helsinki standards. All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) and Soochow University Animal Ethics Review Board (SDY-2022-158-2#).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"95"}}